Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Veritas In Silico Inc. ( (JP:130A) ) just unveiled an announcement.
Veritas In Silico Inc. has successfully completed the patent examination and grant procedures for its innovative Drug Delivery System (DDS) named ‘Perfusio,’ designed for administering nucleic acid therapeutics. This new technology utilizes a dual-structure balloon catheter to enable precise drug delivery to target organs, potentially offering new treatment options while maintaining cost-effectiveness. The DDS is expected to enhance the efficiency of drug administration and reduce liver toxicity, a common concern with nucleic acid therapeutics, thereby strengthening the company’s position in the pharmaceutical industry.
More about Veritas In Silico Inc.
Veritas In Silico Inc. operates in the pharmaceutical industry, focusing on developing mRNA-targeted pharmaceuticals and nucleic acid therapeutics. The company aims to address rare diseases with unmet medical needs by leveraging its technology applicable to both small molecule and nucleic acid therapeutics discovery.
Average Trading Volume: 39,315
Technical Sentiment Signal: Sell
Current Market Cap: Yen3.19B
For detailed information about 130A stock, go to TipRanks’ Stock Analysis page.